Corient Private Wealth LP Takes $4.59 Million Position in Moderna, Inc. $MRNA

Corient Private Wealth LP bought a new stake in shares of Moderna, Inc. (NASDAQ:MRNA) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 65,594 shares of the company’s stock, valued at approximately $4,593,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of MRNA. BlackRock Inc. bought a new position in shares of Moderna in the second quarter valued at approximately $2,142,877,000. Capital World Investors purchased a new stake in Moderna in the 4th quarter worth approximately $378,299,000. Invesco Ltd. lifted its stake in Moderna by 15.7% in the 3rd quarter. Invesco Ltd. now owns 8,216,163 shares of the company’s stock worth $212,223,000 after purchasing an additional 1,115,131 shares in the last quarter. Theleme Partners LLP bought a new position in Moderna in the 2nd quarter valued at $564,272,000. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Moderna by 7.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 4,621,558 shares of the company’s stock valued at $136,290,000 after purchasing an additional 309,126 shares during the period. 75.33% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Moderna in a report on Friday, June 12th. Argus raised Moderna from a “hold” rating to a “buy” rating and set a $180.00 price objective for the company in a research note on Friday. JPMorgan Chase & Co. boosted their target price on Moderna from $40.00 to $77.00 and gave the stock an “underweight” rating in a research report on Friday, August 21st. Royal Bank Of Canada restated a “sector perform” rating and issued a $130.00 target price on shares of Moderna in a research note on Wednesday, August 19th. Finally, Piper Sandler reaffirmed an “overweight” rating on shares of Moderna in a report on Monday, August 3rd. Seven research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, Moderna has a consensus rating of “Hold” and an average price target of $80.53.

Moderna News Summary

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna and Merck reported encouraging results from their cancer-vaccine collaboration, supporting Moderna’s strategy to expand beyond COVID-19 vaccines into personalized oncology treatments. The results have attracted positive attention from market commentator Jim Cramer and helped drive investor enthusiasm. Jim Cramer Called Moderna Inc. and Merck’s Trial Results Encouraging
• Positive Sentiment: Recent clinical evidence has provided a major boost to the broader mRNA sector after a difficult period for the technology. Coverage highlights the potential medical and commercial significance of Moderna’s cancer-vaccine work, particularly as the company seeks to establish growth drivers beyond respiratory vaccines. After a Rough Stretch, mRNA Gets a Boost
• Positive Sentiment: Moderna received FDA approval for updated Spikevax and mNEXSPIKE COVID-19 vaccines targeting the latest SARS-CoV-2 subvariant, as well as mFlusiva, its first mRNA influenza vaccine for adults aged 50 and older. The approvals broaden its respiratory portfolio and could improve the company’s long-term commercial opportunity in seasonal vaccines. What Do Moderna FDA Vaccine Approvals Mean for Its Respiratory Push?
• Positive Sentiment: Argus upgraded Moderna to “Buy,” adding a more bullish analyst view following the company’s clinical and regulatory developments. Argus Upgrades Moderna to Buy
• Neutral Sentiment: Trading volume increased significantly after the analyst upgrade, indicating heightened investor interest and strong momentum in MRNA shares. However, heavy activity can also reflect short-term speculation following the stock’s steep rally. Moderna Sees Large Volume Increase After Analyst Upgrade
• Negative Sentiment: Analysts overall maintain an average “Hold” rating, signaling that Wall Street remains cautious despite the recent clinical progress. The stock’s rapid appreciation has also raised concerns about valuation and the risk of profit-taking if additional trial results do not meet high expectations. Moderna Receives Average Rating of Hold

Moderna Price Performance

Shares of NASDAQ:MRNA opened at $140.34 on Tuesday. The company’s fifty day moving average price is $78.73 and its 200-day moving average price is $60.54. The firm has a market capitalization of $56.03 billion, a price-to-earnings ratio of -17.56 and a beta of 0.91. Moderna, Inc. has a one year low of $22.28 and a one year high of $176.66. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.29 and a quick ratio of 2.18.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Friday, July 31st. The company reported ($1.97) earnings per share for the quarter, beating the consensus estimate of ($2.03) by $0.06. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The firm had revenue of $145.00 million for the quarter, compared to analysts’ expectations of $102.93 million. During the same quarter last year, the company posted ($2.13) EPS. The business’s quarterly revenue was up 2.1% on a year-over-year basis. On average, equities research analysts anticipate that Moderna, Inc. will post -6.11 earnings per share for the current fiscal year.

Insider Transactions at Moderna

In other Moderna news, President Stephen Hoge sold 53,336 shares of the firm’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $51.37, for a total transaction of $2,739,870.32. Following the sale, the president owned 1,483,848 shares in the company, valued at $76,225,271.76. This trade represents a 3.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Thyme Klinger sold 3,471 shares of Moderna stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $50.00, for a total value of $173,550.00. Following the sale, the insider directly owned 67,468 shares of the company’s stock, valued at approximately $3,373,400. This trade represents a 4.89% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 10.80% of the company’s stock.

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.